Differences in the function of parathyroid peptides. What are we measuring?;Diferencias en la función de los péptidos paratiroideos. ¿Qué estamos midiendo?

Nefrologia

Volumn 28, Issue 2, 2008, Pages 123-128

  De La Piedra, Concepción ^a   Fernandez E ^b   Gonzalez Casaus Ma L ^c   Gonzalez Parra E ^c  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

^b HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^c HOSPITAL CENTRAL DE LA DEFENSA GÓMEZ ULLA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PARATHYROID HORMONE;

BLOOD; BLOOD ANALYSIS; EDITORIAL; HUMAN; PHYSIOLOGY; STANDARD;

BLOOD CHEMICAL ANALYSIS; HUMANS; PARATHYROID HORMONE;

EID: 51149119094     PISSN: 02116995     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (26)

1. Díez Pérez A, Puig Manresa J,Martínez Izquierdo MT, Nogués Solan X, Vivancos Lleida J. Hiperparatiroidismo primario. En: Patología ósea metabólica. Ed: S Serrano, J Aubia y ML Mariñoso. Sandoz SAE; Barcelona, 1990.
2. Collip JB. The extraction of a parathyroid hormone which will prevent or control parathyroid tetany and which regualtes the level of blood calcium. J Biol Chem 1925; 63: 395-438.
3. Rodríguez M, Nemeth E, Martin. The calcium-sensing receptor: a key factor in the pathogenesis of secondary hyperparathyroidism. Am J Physiol Renal Physiol 2005; 288: F253-64.
4. Stubbs J, Liu S, Quarles LD. Role of fibroblast growth factor 23 in phosphate homeostasis and pathogenesis of disordered mineral metabolism in chronic kidney disease. Semin Dial 2007; 20: 302-8.
5. D'Amour P, Brossard JH, Rousseau L y cols. Structure of non-(1-84) PTH fragments secreted by parathyroid glands in primary and secondary hyperparathyroidism. Kidney Int 2005; 68: 998-1007.
6. D'Amour P, Brossard JH, Rousseau L y cols. Amino-terminal form of parathyroid hormone (PTH) with immunologic similarities to hPTH (1-84) is overproduced in primary and secondry hyperparathyroidism. Clin Chem 2003; 49: 2037-2044.
7. D'Amour P. Circulating PTH molecular forms: What we know and what we don't. Kidney Int 2006; 70: S29-S33.
8. Nemeth EF. The parathyroid polyhormone hypotesis revisited. Kidney Int 2006; 70: 522.
9. Brown EM, Gamba G, Riccardi D y cols. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature 1993; 366: 575-580.
10. Nguyen-Yamamoto L, Rousseau L, Brossard JH y cols. Synthetic carboxyl-terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology 2001; 142: 136-139.
11. Divieti P, John MR, Juppner H, Bringhurst FR. Human PTH-(7-84) inhibits bone resorption in vitro via actions independent of the type 1 PTH/PTHrP receptor. Endocrinology 2002; 143: 171-176.
12. Slatopolsky E, Finch E, Clay P, Martin D, Sicard G, Singer G, Gao P, Cantor T, Dusso A. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761.
13. Murray TM, Rao LG, Divieti P, Bringhurst FR. Parathyroid Hormone Secretion and Action: Evidencefor Discrete Receptors for the Carboxyl-Terminal Region and Related Biological Actions of Carboxyl-Terminal Ligands. Endocrine Rev 2005; 26 (1): 78-113.
14. Ureña Torres P. The need for reliable serum parathyroid hormone measurements. Kidney Int 2006; 70: 240-243.
15. Nguyen-Yamamoto L, Rousseau L, Brossard JH y cols. Synthetic carboxyl-terminal fragments of PTH decrease ionized calcium concentration in rats by acting on a receptor different from the PTH/PTHrP receptor. Endocrinology 2001; 142: 136-139.
16. Dieveti P, Geller AL, Suliman G. Receptors Specific for the Carboxyl-Terminal Region of Parathyroid Hormone on Bone-Derived Cells: determinants of Ligand Binding and Bioactivity. Endocrinology 2005; 146: 1863-1870.
17. Nussbaum S, Zahradnik R, Lavigne J y cols. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients wth hypercalcemia. Clin Chem 1987; 33: 1364-1367.
18. Sherrard DJ, Hercz G, Pei Y y cols. The spectrum of bone disease in end-stage renal failure- an evolving disorder. Kidney Int 1993; 43: 436-442.
19. Hercz G, Pei Y, Geenwood y cols. Aplastic osteodistrophy without aluminium: the role of «supressed» parathyroid function. Kidney Int 1993; 44: 860-866.
20. Wang M, Hercz G, Sherrard D y cols. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity. Am J Kidney Dis 1995; 26: 836-844.
21. K/DOQI guidelines for the management of renal osteodistrophy. Am J Kidney Dis 2003; 42 (Supl. 3): S1-S201.
22. Souberbielle JC, Boutten A, Carlier MC y cols. Inter-mehod variability in PTH measurement: implication in the care of CKD patients. Kidney Int 2006; 70: 345-350.
23. Torres A, Lorenzo V, Hernández D, Rodríguez JC, Concepción MT, Rodríguez AP, Hernández A, De Bonis E, Darias E, González-Posada JM, Losada M, Rufino M, Felsenfeld AJ, Rodríguez M. Bone disease in predialysis, hemodialysis and CAPD patients: evidence of a better bone response to PTH. Kidney Int 1995; 47: 1434-1442.
24. Coen G, Bonucci E, Ballanti P, Balducci A,Calabria S,Nicolai GA, Fischer MS, Lifrieri F, Manni M, Morosetti M, Moscaritolo E, Sardella D. PTH 1-84 and PTH «7-84» in the noninvasive diagnosis of renal bone disease. Am J Kidney Diseases 2002; 40: 348-354.
25. Cantor T, Yang Z, Caraiani N, Ilamathi E. Lack of comparability of intact parathyroid hormone measurements among comercial assays for end-stage renal disease patients: implication for treatment decisions. Clin Chem 2006; 52: 1771-1776.
26. Foley RN, Li S, Liu J, Gilbertson DT, Chen SC, Collins AJ. The fall and rise of parathyroidectomy in US hemodialysis patients, 1992 to 2002. J Am Soc Nephrol 2005; (1): 210-218.